209 related articles for article (PubMed ID: 33619341)
41. Induction of MHC class I expression by the MHC class II transactivator CIITA.
Martin BK; Chin KC; Olsen JC; Skinner CA; Dey A; Ozato K; Ting JP
Immunity; 1997 May; 6(5):591-600. PubMed ID: 9175837
[TBL] [Abstract][Full Text] [Related]
42. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
43. K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region.
Day NE; Ugai H; Yokoyama KK; Ichiki AT
Leuk Res; 2003 Nov; 27(11):1027-38. PubMed ID: 12859996
[TBL] [Abstract][Full Text] [Related]
44. Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene.
Yang Y; Dai W; Chen Z; Yan Z; Yao Z; Zhang C
Biosci Trends; 2013 Feb; 7(1):50-5. PubMed ID: 23524893
[TBL] [Abstract][Full Text] [Related]
45. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells.
Kong X; Fang M; Li P; Fang F; Xu Y
J Mol Cell Cardiol; 2009 Mar; 46(3):292-9. PubMed ID: 19041327
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.
Lin JH; Lin JY; Chou YC; Chen MR; Yeh TH; Lin CW; Lin SJ; Tsai CH
Blood; 2015 Apr; 125(14):2228-38. PubMed ID: 25631773
[TBL] [Abstract][Full Text] [Related]
47. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha.
Nikcevich KM; Piskurich JF; Hellendall RP; Wang Y; Ting JP
J Neuroimmunol; 1999 Oct; 99(2):195-204. PubMed ID: 10505975
[TBL] [Abstract][Full Text] [Related]
48. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.
Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA
Immunity; 1996 Feb; 4(2):167-78. PubMed ID: 8624807
[TBL] [Abstract][Full Text] [Related]
49. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
Dong Y; Rohn WM; Benveniste EN
J Immunol; 1999 Apr; 162(8):4731-9. PubMed ID: 10202014
[TBL] [Abstract][Full Text] [Related]
50. A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma.
Siegrist CA; Martinez-Soria E; Kern I; Mach B
J Exp Med; 1995 Dec; 182(6):1793-9. PubMed ID: 7500024
[TBL] [Abstract][Full Text] [Related]
51. Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.
Bhat KP; Truax AD; Greer SF
J Biol Chem; 2010 Aug; 285(34):25893-903. PubMed ID: 20538595
[TBL] [Abstract][Full Text] [Related]
52. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
54. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
55. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma).
Xu Y; Wang L; Butticè G; Sengupta PK; Smith BD
J Biol Chem; 2004 Oct; 279(40):41319-32. PubMed ID: 15247294
[TBL] [Abstract][Full Text] [Related]
56. The induction of major histocompatibility complex class II expression is sufficient for the direct activation of human CD4+ T cells by porcine vascular endothelial cells.
Yun S; Rose ML; Fabre JW
Transplantation; 2000 Mar; 69(5):940-4. PubMed ID: 10755554
[TBL] [Abstract][Full Text] [Related]
57. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
Yun S; Gustafsson K; Fabre JW
Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
[TBL] [Abstract][Full Text] [Related]
58. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
59. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III.
Holling TM; van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Jan; 168(2):763-70. PubMed ID: 11777970
[TBL] [Abstract][Full Text] [Related]
60. Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
Ghorpade DS; Holla S; Sinha AY; Alagesan SK; Balaji KN
J Biol Chem; 2013 Jul; 288(28):20592-606. PubMed ID: 23733190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
